PMID- 16723471
OWN - NLM
STAT- MEDLINE
DCOM- 20060703
LR  - 20220317
IS  - 0146-0404 (Print)
IS  - 0146-0404 (Linking)
VI  - 47
IP  - 6
DP  - 2006 Jun
TI  - Inhibitory effects of lutein on endotoxin-induced uveitis in Lewis rats.
PG  - 2562-8
AB  - PURPOSE: Lutein deposits in the macula and lens of human eyes with high 
      concentration and is well known as an eye-protective nutrient for its beneficial 
      effects on eye disease such as age-related macular degeneration and cataract. The 
      purpose of the present study was to investigate the effects of lutein on 
      endotoxin-induced uveitis (EIU) in rats. METHODS: EIU was induced in male Lewis 
      rats by subcutaneous injection of 200 microg lipopolysaccharide. Lutein or 
      dexamethasone was administered intravenously at 30 minutes before, at the same 
      time as, and at 30 minutes after LPS treatment. The aqueous humor was collected 
      at 24 hours after LPS injection, the number of infiltrating cells, the protein 
      concentration, and the levels of nitric oxide (NO), tumor necrosis factor 
      (TNF)-alpha, interleukin (IL)-6, prostaglandin (PG)-E2, monocyte chemoattractant 
      protein-1 (MCP-1), and macrophage inflammatory protein (MIP)-2 in the aqueous 
      humor were determined. Immunohistochemical staining with a monoclonal antibody 
      against activated nuclear factor (NF)-kappaB was performed to evaluate the effect 
      of lutein on NF-kappaB activation in the iris-ciliary body (ICB) of rats. A mouse 
      macrophage cell line (RAW264.7 cells) was stimulated with LPS in the presence or 
      absence of lutein. Expression of inducible NO synthase (iNOS), cyclooxygenase-2 
      (COX-2), and degradation of inhibitor kappaB (IkappaB) were analyzed by Western 
      blot analysis. RESULTS: Lutein suppressed the development of EIU in a 
      dose-dependent fashion. The anti-inflammatory effect of 100 mg/kg lutein was as 
      strong as that of 1 mg/kg dexamethasone. Treatment with lutein reduced the 
      concentrations of NO, TNF-alpha, IL-6, PGE2, MCP-1, and MIP-2 in aqueous humor. 
      Lutein also suppressed the activation of NF-kappaB in the ICB as well as iNOS and 
      COX-2 expression and IkappaB degradation in RAW cells. CONCLUSIONS: These 
      findings indicate that lutein has anti-inflammatory effects on EIU by inhibiting 
      the NF-kappaB dependent signaling pathway and the subsequent production of 
      proinflammatory mediators.
FAU - Jin, Xue-Hai
AU  - Jin XH
AD  - Department of Ophthalmology, Hokkaido University Graduate School of Medicine, 
      Sapporo, Japan.
FAU - Ohgami, Kazuhiro
AU  - Ohgami K
FAU - Shiratori, Kenji
AU  - Shiratori K
FAU - Suzuki, Yukari
AU  - Suzuki Y
FAU - Hirano, Takeshi
AU  - Hirano T
FAU - Koyama, Yoshikazu
AU  - Koyama Y
FAU - Yoshida, Kazuhiko
AU  - Yoshida K
FAU - Ilieva, Iliyana
AU  - Ilieva I
FAU - Iseki, Ken
AU  - Iseki K
FAU - Ohno, Shigeaki
AU  - Ohno S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cytokines)
RN  - 0 (I-kappa B Proteins)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (NF-kappa B)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - X72A60C9MT (Lutein)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aqueous Humor/metabolism
MH  - Blotting, Western
MH  - Cell Line
MH  - Ciliary Body/drug effects/metabolism
MH  - Cyclooxygenase 2/metabolism
MH  - Cytokines/metabolism
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - I-kappa B Proteins/metabolism
MH  - Iris/drug effects/metabolism
MH  - Lipopolysaccharides
MH  - Lutein/*pharmacology
MH  - Macrophages/metabolism
MH  - Male
MH  - Mice
MH  - Microscopy, Confocal
MH  - NF-kappa B/metabolism
MH  - Nitric Oxide Synthase Type II/metabolism
MH  - Rats
MH  - Rats, Inbred Lew
MH  - Salmonella typhimurium
MH  - Uveitis, Anterior/metabolism/*prevention & control
EDAT- 2006/05/26 09:00
MHDA- 2006/07/04 09:00
CRDT- 2006/05/26 09:00
PHST- 2006/05/26 09:00 [pubmed]
PHST- 2006/07/04 09:00 [medline]
PHST- 2006/05/26 09:00 [entrez]
AID - 47/6/2562 [pii]
AID - 10.1167/iovs.05-1429 [doi]
PST - ppublish
SO  - Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2562-8. doi: 10.1167/iovs.05-1429.